GlobeNewswire·Nov 19, 2025, 8:00 AM ET

Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9

BioVie Inc. (NASDAQ: BIVI) will host a free investor webinar on December 9, 2025, at 4:15 p.m. ET, hosted by RedChip Companies.
CEO Cuong Do will present on bezisterim (NE3107), a first-in-class oral small molecule targeting inflammation & insulin resistance for Alzheimer's, Parkinson's, & Long COVID.
Clinical data for bezisterim has shown improved cognition, motor function, & reduced neuroinflammation across studies.
The presentation will also cover progress on BIV201, a late-stage orphan drug candidate for refractory ascites in liver cirrhosis patients.
BIV201 holds FDA Fast Track status & has received FDA guidance regarding Phase 3 clinical testing design.
The active agent in BIV201 is approved in the U.S. & approximately 40 countries for complications of advanced liver cirrhosis.
A live Q&A session with BioVie management will follow the presentation.
Registration is available via the RedChip website, with pre-submitted questions accepted via email or during the live event.
The press release includes standard forward-looking statement disclaimers regarding risks such as capital raising, clinical study completion, & regulatory approval.